Morgan Stanley Assumes Regenxbio Inc. (RGNX) at Overweight

Morgan Stanley analyst Judah Frommer assumes coverage on Regenxbio Inc. (NASDAQ: RGNX) with a Overweight rating and a price target of $22.00.

The analyst comments: "We assume coverage of RGNX at OW rating. We appreciate the attractiveness of gene therapy in concept for VEGF-mediated diseases given the unmet need, but caution that subretinal delivery may limit commercial uptake and suprachoroidal delivery data presented to date is still early, in our view. Acknowledging the difficulty of cross-trial comparisons in this space, the efficacy of suprachoroidal RGX-314 appears to be numerically lower than competitors (i.e. competing gene therapies and TKIs); additionally, the need for steroid prophylaxis to mitigate the greater inflammation risk implies potential additional burden for patients/clinicians (though the taper is short vs. competitors). We will continue to monitor both programs as data is generated and as a fourth dose level is explored for suprachoroidal delivery."

For an analyst ratings summary and ratings history on Regenxbio Inc. click here. For more ratings news on Regenxbio Inc. click here.

Shares of Regenxbio Inc. closed at $11.14 yesterday.

You May Also Be Interested In

• Raymond James Starts Civeo (CVEO) at Strong Buy
• Loop Capital Starts Rubrik Inc (RBRK) at Buy
• Superior Group of Companies Inc. (SGC) PT Raised to $18 at DA Davidson